 SEATTLE--BUSINESS WIRE--Silverback Therapeutics, Inc. Nasdaq: SBTX Silverback, a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a business update. The second quarter was notable for the significant progr 